KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Acquisitions (2023 - 2025)

Regeneron Pharmaceuticals (REGN) has 4 years of Acquisitions data on record, last reported at $300000.0 in Q4 2025.

  • For Q4 2025, Acquisitions fell 97.39% year-over-year to $300000.0; the TTM value through Dec 2025 reached $14.8 million, down 77.71%, while the annual FY2025 figure was $3.3 million, 80.0% down from the prior year.
  • Acquisitions reached $300000.0 in Q4 2025 per REGN's latest filing, down from $3.0 million in the prior quarter.
  • Across five years, Acquisitions topped out at $230.3 million in Q3 2022 and bottomed at $300000.0 in Q4 2025.
  • Average Acquisitions over 4 years is $50.0 million, with a median of $7.6 million recorded in 2023.
  • Peak YoY movement for Acquisitions: surged 202.63% in 2024, then crashed 97.39% in 2025.
  • A 4-year view of Acquisitions shows it stood at $230.3 million in 2022, then plummeted by 98.35% to $3.8 million in 2023, then soared by 202.63% to $11.5 million in 2024, then plummeted by 97.39% to $300000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Acquisitions were $300000.0 in Q4 2025, $3.0 million in Q3 2025, and $11.5 million in Q4 2024.